What does the best evidence say about short-term use in healthy adults?
For a healthy adult taking an antihistamine occasionally for allergies or motion sickness, the main risk is temporary drowsiness and slower reaction times, not permanent brain damage. The most rigorous analysis on this question comes from a 2022 Cochrane review of nine randomized controlled trials (658 participants) looking at antihistamines for motion sickness [2]. That review found that while antihistamines were more likely to cause sedation than placebo (66% of users felt drowsy vs. 44% on placebo), there was no significant difference in reports of 'impaired cognition' (29% on antihistamines vs. 33% on placebo) [2]. This means that for short-term use in otherwise healthy people, measurable cognitive impairment is not a guaranteed or even common side effect.
However, the same Cochrane review notes that the evidence for impaired cognition was rated 'low certainty' because the studies were small and didn't use sensitive cognitive tests [2]. So while the data is reassuring, it's not definitive. The key takeaway is that the immediate, noticeable effect is sedation, not a subtle cognitive decline that persists after the drug wears off.
When should you actually worry about long-term cognitive effects?
The concern about long-term cognitive impairment shifts dramatically when you look at older adults, people with dementia, or those using antihistamines daily for months or years. A 2024 review on drug-induced cognitive impairment explicitly names 'first-generation antihistamines' as a drug class that can cause cognitive issues, including mild cognitive impairment and delirium, especially in the elderly [4]. This is because these drugs block acetylcholine, a brain chemical critical for memory and learning, and older brains are more sensitive to this effect.
This warning is backed by a large 2022 study of over 15,000 people with dementia, which found that taking any sedative medication (including antihistamines) at the time of dementia diagnosis was linked to faster cognitive decline and a higher risk of hospitalization [3]. Specifically, antihistamines were among the drugs associated with 'accelerated cognitive decline' [3]. This doesn't prove antihistamines cause dementia, but it strongly suggests that in people whose brains are already vulnerable, these drugs can make things worse. A separate 2021 study of elderly residents in long-term care actually found that antihistamine use was associated with *better* cognitive scores [5], but that likely reflects that healthier residents were more able to take them, not that the drugs protect the brain.
The gap between best-case and worst-case scenarios
The evidence creates a clear picture: the risk of long-term cognitive impairment from antihistamines depends almost entirely on who is taking them and for how long. In the best-case scenario—a young or middle-aged adult using a first-generation antihistamine occasionally—the main risk is temporary sedation, and the Cochrane review found no clear signal for lasting cognitive harm [2]. In the worst-case scenario—an elderly person with existing cognitive vulnerability taking a first-generation antihistamine daily—the risk of accelerating cognitive decline is real and supported by multiple studies [3][4].
This gap is why you'll hear conflicting advice. A doctor might say 'antihistamines are fine for hay fever' (which is true for short-term use in healthy people) while a geriatrician might warn against them for older patients (because the risk-benefit ratio is different). The 2024 review [4] and the dementia cohort study [3] converge on the same warning: chronic use, especially in the elderly, is where the danger lies. The 2022 Cochrane review [2] and the 2021 long-term care study [5] don't contradict this—they simply studied different populations and durations of use.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2021 to 2024, 1 from 2024 or later, 4 in Q1 journals, collectively cited 205 times — selected as the most relevant from 10 studies that passed quality screening, drawn from 57 papers retrieved from a database of over 500 million.
Sources used in this answer
Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: a randomised controlled trial
In a randomized controlled trial of 200 ICU patients on ventilators, early physical and occupational therapy reduced the rate of cognitive impairment at 1 year from 43% to 24% (absolute difference -19.2%, p=0.0043), showing that non-drug interventions can improve long-term cognitive outcomes.
Antihistamines for motion sickness
In a Cochrane review of 9 RCTs (658 participants) on antihistamines for motion sickness, antihistamines increased sedation (66% vs 44% with placebo) but did not significantly increase reports of impaired cognition (29% vs 33%), though the evidence was low certainty.
Sedation‐associated medications at dementia diagnosis, their receptor activity, and associations with adverse outcomes in a large clinical cohort
In a retrospective cohort of 15,210 dementia patients, taking any sedative medication (including antihistamines) at diagnosis was associated with accelerated cognitive decline and higher hospitalization risk; antihistamines specifically were linked to faster cognitive decline.
Drug-Induced Cognitive Impairment
In a 2024 review of drug-induced cognitive impairment, first-generation antihistamines are explicitly listed as a drug class that can cause cognitive issues, including mild cognitive impairment and delirium, particularly in older adults and with chronic use.
Factors associated with cognitive performance in residents of long-term care facilities in Northeast Mexico.
In a cross-sectional study of 280 institutionalized older adults in Mexico, antihistamine use was inversely associated with cognitive impairment (OR=0.322), meaning users were less likely to have impairment, likely reflecting a healthier user population.